Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Technology Advances: CISH technology Facilitates Assay of HER2 Expression
Dorothy J. Schirf, MD, MDLinx Oncology
Today's Oncology News: VEGFb Designated Orphan Drug Status By FDA
D Scott Cunningham MD, PhD, MDLinx Oncology
  See all
Papillary renal cell carcinoma Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Papillary renal cell carcinoma: clinicopathological characteristics in 40 patients
Clinical and Experimental Nephrology, 05/13/08
Print     Email This Article     Save in My Library   Free Abstract
Kosaka T et al. – Papillary renal cell carcinomas (PRCCs) include two distinct morphological types of tumor: type-2 features (large cells and eosinophilic cytoplasm) are less favorable than type-1 (small cells and pale cytoplasm)

Methods

  • Review of 40 cases of PRCC (20 each type), with focus on distinct clinicopathologic difference and response to cytokine therapy
  • PRCCs classified by Delahunt and Eble criteria

Results
  • No lymphatic or vascular invasion or distant metastasis in type-1
  • Nuclear grade was low in all type-1Nuclear grade and positive rate of vascular invasion were significantly higher in type-2
  • Distant metastasis detected preoperatively in type-2 3 pts
  • IL-2 therapy response in 1 pt with metastatic type-2 PRCCs

 

Sponsor
--- RENAL/UROLOGIC TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.